Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus

被引:14
作者
Arhin, Francis F. [1 ]
Sarmiento, Ingrid [1 ]
Parr, Thomas R., Jr. [1 ]
Moeck, Gregory [1 ]
机构
[1] Medicines Co, St Laurent, PQ H4S 2A1, Canada
关键词
Lipoglycopeptide; Inoculum effect; Resistance trends; INTERMEDIATE; VANCOMYCIN;
D O I
10.1016/j.ijantimicag.2011.09.017
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In this study, the impact of inoculum density on the growth inhibitory and killing activities of oritavancin and comparators (vancomycin, daptomycin and linezolid) in vitro against four Staphylococcus aureus strains at clinically relevant drug concentrations was studied. Broth microdilution and time-kill assays were performed using a standard inoculum [ca. 10(5) colony-forming units (CFU)/mL as per Clinical and Laboratory Standards Institute (CLSI) guidelines] and a high inoculum (ca. 10(7) CFU/mL). Whereas minimal inhibitory concentrations (MICs) of comparators were 2-8-fold higher when tested at high inoculum, oritavancin MICs were 16-fold higher for all strains at the high inoculum relative to the standard inoculum. However, in time-kill assays, when tested at its fC(min) [trough concentration of free (non-protein-bound) drug] and fC(max) (peak concentration of non-protein-bound drug), oritavancin retained its bactericidal activity against a vancomycin-susceptible, meticillin-susceptible S. aureus (VS-MSSA) strain and a vancomycin-susceptible, meticillin-resistant S. aureus (VS-MRSA) strain both at standard and high inocula. At its fC(max), oritavancin was bactericidal at standard inoculum but not at high inoculum against two vancomycin-intermediate S. aureus (VISA) strains. Against both VISA strains at standard inoculum, oritavancin at its fC(min) reduced cell density by between 2 and 3 log (bacteriostatic), predicting that it will retain activity against certain VISA infections. However, oritavancin had no substantial growth inhibitory effect against either VISA strain at high inoculum, suggesting that in rare VISA infections with an anticipated high bacterial burden such as endocarditis, alternative oritavancin dosing strategies, including combinations with other agents, may be explored. (C) 2011 Elsevier B. V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:159 / 162
页数:4
相关论文
共 15 条
[11]   Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium [J].
McKay, Geoffrey A. ;
Beaulieu, Sylvain ;
Arhin, Francis F. ;
Belley, Adam ;
Sarmiento, Ingrid ;
Parr, Thomas, Jr. ;
Moeck, Gregory .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (06) :1191-1199
[12]   Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium [J].
Mercier, RC ;
Houlihan, HH ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1307-1312
[13]  
Nadrah Kristina, 2011, Chemother Res Pract, V2011, P619321, DOI 10.1155/2011/619321
[14]   Vancomycin intermediate-resistant Staphylococcus aureus [J].
Turco, TF ;
Melko, GP ;
Williams, JR .
ANNALS OF PHARMACOTHERAPY, 1998, 32 (7-8) :758-760
[15]   Improved Antimicrobial Activity of Linezolid against Vancomycin-Intermediate Staphylococcus aureus [J].
Watanabe, Yukiko ;
Neoh, Hui-min ;
Cui, Longzhu ;
Hiramatsu, Keiichi .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (11) :4207-4208